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Abstract
Background: Quinine is still recommended as an effective therapy for severe cases of Plasmodium falciparum
malaria, but the parasite has developed resistance to the drug in some cases. Investigations into the genetic basis for
quinine resistance (QNR) suggest that QNR is complex and involves several genes, with either an additive or a
pairwise effect. The results obtained when assessing one of these genes, the plasmodial Na
+/H
+ exchanger, Pfnhe-1,
were found to depend upon the geographic origin of the parasite strain. Most of the associations identified have
been made in Asian strains; in contrast, in African strains, the influence of Pfnhe on QNR is not apparent. However, a
recent study carried out in Kenya did show a significant association between a Pfnhe polymorphism and QNR. As
genetic differences may exist across the African continent, more field data are needed to determine if this association
exists in other African regions. In the present study, association between Pfnhe and QNR is investigated in a series of
isolates from central Africa.
Methods: The sequence analysis of the polymorphisms at the Pfnhe-1 ms4760 microsatellite and the evaluation of
in vitro quinine susceptibility (by isotopic assay) were conducted in 74 P. falciparum isolates from the Republic of
Congo.
Results: Polymorphisms in the number of DNNND or NHNDNHNNDDD repeats in the Pfnhe-1 ms4760
microsatellite were not associated with quinine susceptibility.
Conclusions: The polymorphism in the microsatellite ms4760 in Pfnhe-1 that cannot be used to monitor quinine
response in the regions of the Republic of Congo, where the isolates came from. This finding suggests that there
exists a genetic background associated with geographic area for the association that will prevent the use of Pfnhe
as a molecular marker for QNR. The contribution of Pfnhe to the in vitro response to quinine remains to be
assessed in other regions, including in countries with different levels of drug pressure.
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Quinine (QN) remains a first-line drug for the treatment
of severe malaria that is still used as a second-line ther-
apy for uncomplicated malaria in many countries [1].
Despite the efficacy of QN against chloroquine-resistant
Plasmodium falciparum isolates, reports of QN resis-
tance (QNR) have been increasing. In the 1980s, the fre-
quency of clinical failures increased in Southeast Asia
and Africa [2-4]. The mechanism of QNR is complex,
multigenic, and not well understood. QNR has been
associated with mutations in both the P. falciparum
multidrug resistance gene mdr1 (Pfmdr1)[ 5 ]a n dt h e
chloroquine resistance transporter gene Pfcrt [6]. Other
genetic polymorphisms, such as mutations in the resis-
tance protein gene Pfmrp [7] and variations of microsa-
tellite length in the sodium/hydrogen exchanger gene
Pfnhe-1 [8], may contribute to QNR. Using quantitative
trait loci (QTL) on the genetic cross of HB3 and Dd2
strains, Ferdig et al identified genes on chromosome 5,
encoding Pfmdr1, on chromosome 7, encoding Pfcrt
and on chromosome 13, encoding Pfnhe-1,w h i c hw e r e
associated with QN reduced susceptibility [8]. Sequences
of Pfnhe-1 showed multiple and complex variations such
as point polymorphisms at three separate codons
(790, 894 and 950) and as microsatellite variations in
three different repeat sequences (msR1, ms3580 and
ms4760). However, the three point polymorphisms and
microsatellite polymorphisms msR1 and ms3580 showed
no significant association with QN susceptibility. The
investigations of the microsatellite ms4760 polymorph-
isms in culture-adapted isol a t e sf r o ma r o u n dt h ew o r l d
showed that an increased number of the amino
acid motif DNNND was associated with a decreased
QN susceptibility, and that an increased number of
NHNDNHNNDDD motifs was associated with an
increased QN susceptibility [8,9]. The association of two
repeats with a high QN inhibitory concentration of 50%
(IC50) was found in a case of QN clinical failure in a tra-
veller from Senegal [10]. In contrast, a recent multivari-
ate analysis performed on 83 freshly collected clinical
isolates from Madagascar and 13 African countries did
not find an association between QN susceptibility and
Pfnhe-1 microsatellite polymorphisms [11]. A similar
absence of association was observed in 91 isolates from
various countries on different continents (Pelleau S.
et al. submitted). Given that the influence of Pfnhe on
QN susceptibility has been shown to be strain-depen-
dent, these apparently conflicting results may be
explained, in part, by differences in the geographic ori-
gin of the parasites analysed, as their local selection his-
tory and genetic background varies.
Thus, further epidemiological investigation is required
to determine the context in which Pfnhe can be used as
a molecular marker of QNR. In this work, ms4760 poly-
morphism was analized and its association tested with
in vitro susceptibility to QN in African isolates from a
single geographical region, Pointe-Noire in the Republic
of Congo.
Methods
Reference culture-adapted strains and clinical isolates of
Plasmodium falciparum
Between March 2005 and January 2006, 74 P. falciparum
clinical isolates were collected from patients with uncom-
plicated malaria at the Medical Service of Total Explora-
tion et Production, Pointe-Noire (Republic of Congo)
[12]. Two cloned strains of P. falciparum were used for
quality control (3D7 Africa and W2 Indochina). These
clones were obtained from MR4-ATCC (Manassas, VA,
U S A ) .T h e yw e r em a i n t a i n e di nc u l t u r ei nR P M I1 6 4 0
(Invitrogen, Paisley, UK) that was supplemented with
10% human serum (Abcys S.A. Paris, France) and buf-
fered with 25 mM HEPES and 25 mM NaHCO3.T h e
parasites were grown in type A+ human blood under
controlled atmospheric conditions (10% O2,5 %C O 2, and
85% N2) at 37°C with a humidity of 95%. They were syn-
chronized twice with sorbitol before use [13]. Clonality
was verified using PCR genotyping of the polymorphic
genetic markers, msp1 and msp2, and the microsatellite
loci [14,15].
In vitro assay
The QN was purchased from Sigma (Saint Louis, MO,
USA). The QN was first dissolved in methanol and then
diluted in water to obtain final concentrations ranging
from 5 to 3200 nM.
For the in vitro isotopic microtest, 200 μl of the sus-
pension of synchronous parasitized red blood cells (final
parasitaemia, 0.5%; final haematocrit, 1.5%) per well
were plated in 96-well plates that contained serial QN
concentrations. Parasite growth was assessed by adding
1 μCi of tritiated hypoxanthine with a specific activity of
14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to
each well at time zero. The plates were then incubated
for 48 h under controlled atmospheric conditions.
Immediately after incubation, the plates were frozen and
then thawed to lyse the erythrocytes. The contents of
each well were collected on standard filter microplates
(Unifilter GF/B; Perkin-Elmer) and washed using a cell
harvester (Filter-Mate Cell Harvester; Perkin-Elmer).
The filter microplates were dried and 25 μl of a scintilla-
tion cocktail (Microscint O; Perkin-Elmer) was added to
each well. The radioactivity incorporated by the para-
sites was then measured using a scintillation counter
(Top Count; Perkin-Elmer). The drug concentration that
could inhibit 50% of the parasite growth (IC50)w a s
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concentration at which the incorporation of tritiated
hypoxanthine by the parasite was 50% of that incorpo-
rated in the drug-free, control wells. IC50 values were
determined using a non-linear regression analysis of
log-based dose-response curves (Riasmart, Packard,
Meriden, USA).
Genotyping of the Pfnhe ms4760 microsatellite
polymorphisms
Parasite DNA from 100 μl of infected blood was
extracted using the E.Z.N.A. Blood DNA kit (Omega
Bio-Tek, GA, USA). A sequence containing the pre-
viously described ms4760 microsatellite [8] was ampli-
fied using the pfnhe-3802F 5’-TTATTAAATGAA
TATAAAGA-3’ and pfnhe-4322R 5’-TTTTTTATCAT
TACTAAAGA-3’ primers. Sequencing was performed
using ABI Prism Big Dye Terminator v1.1 Cycle
Sequencing Ready Reaction Kits (Applied Biosystems,
CA, USA), as directed by the manufacturer. Sequences
were analysed with BioEdit sequence alignment editor
(version 7.0.9.0) software.
Statistical analysis
Data were analysed using R software (version 2.10.1)
and GraphPad Prism (version 5.01). Differences between
the median QN IC50 values of isolates harbouring one,
two or three DNNND repeats were tested using the
Kruskal-Wallis test. The median QN IC50 values of iso-
lates with one or two NHNDNHNNDDD repeats were
compared using the Mann Whitney test.
Results
The mean QN IC50 of the 74 isolates was 381.9 nM,
CI95% [330.7-433.1] (min-max: 36-1097 nM). Four iso-
lates (5.4%) had a QN IC50 > 800 nM (Table 1) that cor-
responds to the in vitro QNR threshold. Twenty-seven
different Pfnhe-1 genotypes were observed among the 74
isolates, and eighteen were identified as new genotypes
(GenBank accession numbers FJ392810 to FJ392827).
The DNNND repeats varied from 1 to 3. There was no
statistically significant association (p = 0.84) between the
median QN IC50 value and the number of DNNND
repeats (medians at 335, 316 and 330 nM, for isolates
harbouring one, two or three repeats, respectively)
(Figure 1). No statistically significant association was
observed (p = 0.92) between the median QN IC50 value
of isolates and the number of NHNDNHNNDDD
repeats (medians at 328 and 329 nM, for isolates with
one and two repeats, respectively).
Discussion
QN has been used to treat malaria for more than
350 years in Africa, with little emergence and spread of
resistance. QN remains the first line anti-malarial drug
for the treatment of complicated malaria in Europe and
Africa. However, despite the efficacy of QN against
chloroquine-resistant strains, the emergence of QN
resistance has been observed. The first cases of QN clin-
ical failure were observed in Brazil and Asia in the
1960s; then in the 1980s, clinical failures became more
frequent in Southeast Asia, South America and Africa.
However, QN resistance is not yet a significant problem
in Africa, and QN remains the first-line drug to treat
severe malaria and a second-line therapy for uncompli-
cated malaria in some areas of Africa.
Although some reports of QN treatment failure
exist, it is difficult to confirm QN resistance because
of the short elimination half-life of the drug, the
requirement to administer it three times a day for at
least five days, drug intolerance that often leads to
p o o rc o m p l i a n c ea n dal a c ko fr e l i a b l ed a t ao nt h e
correlation between QN IC50 and clinical failure. Max-
imizing the efficacy and longevity of QN as a tool for
the control of malaria will depend critically on the
pursuit of intensive research toward the identification
of in vitro markers of QNR and the implementation of
in vitro and in vivo surveillance programs, such as
those championed by the Worldwide Antimalarial
Resistance Network [16,17]. Specifically, there is a
need to identify molecular markers that effectively
predict QN resistance and enable the active surveil-
lance of temporal trends in parasite susceptibility [18].
The present study aimed to test the association
between the Pfnhe polymorphism and QN susceptibil-
ity in clinical isolates from Pointe-Noire in Congo to
assess the validity of Pfnhe as a molecular marker of
QN susceptibility in this region.
The level of susceptibility to QN remained high, with
a mean QN IC50 of 382 nM and with 4/74 isolates
(5.4%) that exceed the QNR threshold of 800 nM [19].
The threshold at which QN in vitro susceptibility is con-
sidered to be compromised is arbitrary, and different
studies have set the following thresholds: 300 nM [20],
500 nM [21] or 800 nM. If a QNR threshold of 500 nM
is applied here, 19/74 isolates exceed this value. These
results suggest that QN treatment is still effective
against the chloroquine-resistant parasites that are
found in this area, where the prevalence of chloroquine-
resistant parasites has reached 75% [12].
A high level of Pfnhe-1 microsatellite sequence poly-
morphisms was found (27 genotypes for 74 isolates).
Previous studies reported from 8 genotypes for 71 iso-
lates [8] to 35 for 60 isolates [22]. DNNND and
NHNDNHNNDDD repeat numbers ranged from 1 to 3
and 1 to 2, respectively. However, neither DNNND nor
NHNDNHNNDDD repeat polymorphisms were linked
to QN susceptibility.
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Page 3 of 7Table 1 In vitro susceptibility and Pfnhe-1 polymorphisms of the 74 Plasmodium falciparum isolates from the Republic
of Congo
Isolates Cpm
without drug
Cpm
With highest QN
concentration
QN IC50 No DNNND repeat No NHNDNHNNDDD
repeat
No genotype profile
16517 23404 1440 1097 3 2 ms4760-27
16612 49650 8273 888 1 2 ms4760-3
16520 6512 1077 882 1 2 ms4760-3
16094 2007 620 862 2 1 ms4760-24
16980 2151 980 782 2 2 ms4760-33
17267 2558 455 776 2 2 ms4760-1
16631 1807 282 750 1 2 ms4760-3
16698 1263 353 740 2 1 ms4760-6
16960 2011 714 689 2 2 ms4760-1
16958 19732 861 645 3 2 ms4760-30
16983 3710 943 627 3 2 ms4760-1
16957 19773 1300 615 1 2 ms4760-29
16966 2264 545 604 2 2 ms4760-31
16941 18540 1175 576 1 2 ms4760-3
16991 2804 815 567 1 1 ms4760-36
16953 5675 1249 564 1 2 ms4760-12
16539 44532 4112 537 1 2 ms4760-3
17250 6558 606 506 1 2 ms4760-3
16942 10927 1163 502 1 2 ms4760-3
16959 9886 914 488 2 2 ms4760-1
17008 2151 961 482 1 2 ms4760-35
16986 2302 624 481 2 2 ms4760-1
16968 8477 962 457 2 2 ms4760-1
17249 1276 412 408 1 2 ms4760-22
17216 3179 539 404 1 2 ms4760-38
17253 9717 1091 396 2 1 ms4760-6
16987 7232 938 388 3 1 ms4760-15
16349 28606 2048 377 3 1 ms4760-25
17231 3545 389 354 1 2 ms4760-39
16518 8912 1361 351 3 1 ms4760-7
16955 9379 1188 346 3 2 ms4760-27
17211 6451 655 346 1 2 ms4760-3
16695 27421 2316 341 1 2 ms4760-3
16996 1347 597 340 2 2 ms4760-34
17208 18356 1208 335 1 2 ms4760-3
16536 6617 847 333 2 2 ms4760-1
16365 4631 724 332 1 2 ms4760-22
16979 7449 990 326 2 2 ms4760-18
17202 11053 929 319 1 2 ms4760-3
16364 12210 1990 316 2 2 ms4760-26
16331 8912 1113 314 3 2 ms4760-9
15868 1530 498 309 1 2 ms4760-22
16610 4063 961 305 3 1 ms4760-7
16535 16007 1274 291 3 1 ms4760-15
16323 43074 5859 290 1 2 ms4760-12
16992 9464 1111 276 1 2 ms4760-12
17237 12385 873 269 1 2 ms4760-3
17305 21667 1398 269 2 2 ms4760-3
16305 11269 917 265 1 2 ms4760-3
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Page 4 of 7Table 1 In vitro susceptibility and Pfnhe-1 polymorphisms of the 74 Plasmodium falciparum isolates from the Republic
of Congo (Continued)
17303 18553 1646 264 2 2 ms4760-1
17212 2755 520 259 1 2 ms4760-3
16304 16194 738 254 2 2 ms4760-1
17241 5758 447 254 1 2 ms4760-3
16970 2359 705 247 1 1 ms4760-32
16995 7642 1004 247 2 2 ms4760-1
17210 11018 1370 244 1 2 ms4760-22
17233 12100 956 231 2 1 ms4760-6
17265 1593 238 226 2 2 ms4760-1
17214 2421 316 224 2 2 ms4760-37
17209 3499 680 216 3 2 ms4760-9
17007 3633 1159 212 3 2 ms4760-9
16116 11417 999 204 2 2 ms4760-18
17201 25594 2530 204 1 1 ms4760-36
17304 24453 1982 199 2 2 ms4760-1
16086 10918 699 174 3 1 ms4760-15
17283 4391 315 146 3 2 ms4760-1
17010 2897 1103 141 3 2 ms4760-9
16117 17474 1291 121 2 2 ms4760-1
16078 1654 396 106 2 2 ms4760-1
16085 5229 707 86 2 1 ms4760-6
17301 39337 2016 84 1 2 ms4760-12
15867 6893 739 73 1 2 ms4760-3
16091 17320 1695 67 2 2 ms4760-1
16077 4539 353 36 1 2 ms4760-23
Cpm = count per minute.
IC50 = Inhibitory concentration 50% in nM.
QN = quinine.
Pfnhe- 1 ms4760 microsatellite genotype profiles according to the GenBank.
Figure 1 Distribution of quinine (QN) IC50 versus the repeats number of DNNND or NHNDNHNNDDD. The horizontal bars indicate
median values.
Briolant et al. Malaria Journal 2011, 10:37
http://www.malariajournal.com/content/10/1/37
Page 5 of 7According to this study and previous studies, the asso-
ciation between QN in vitro susceptibility and the
Pfnhe-1 microsatellite genotype appears to be geographi-
cally dependent.
One explanation for this could be variation in genetic
background. A specific genetic background observed in
Asia may allow the observed contribution of Pfnhe poly-
morphism on QN in vitro susceptibility. This explanation
is consistent with: i) the first evidence of Pfnhe-QNR
association from QTL analysis using Americano-Asian
cross strains [8], ii) that most associations identified have
been shown among Asian strains [8,9,22] and iii) that at
least 5 genes spanning the P. falciparum genome influ-
ence the QNR in vitro phenotype with an additive effect
or with pairwise interactions [8].
Additionally, these genetic dissimilarities between
African and Asian plasmodial populations may be
accentuated by different local selection histories. The
best-documented genomic modifications by a local
selection process relate to drug pressure. Several studies
have shown that drug pressure may involve extended
linkage disequilibrium around a drug resistance asso-
ciated gene [23]. This is characterized by a strong
genetic diversity loss, called a selective sweep. This pro-
cess stretch may be modified by: i) drug use and
ii) malaria transmission level. A reduced drug use and
higher malaria transmission level in Africa would be
consistent with the lower selective sweep and an
absence of linkage disequilibrium between Pfnhe and
other cooperative drug response genes or selected com-
pensatory mutations. For example, QTL analysis on
chromosome 13 located 60 genes of unknown function
as being close to Pfnhe [8]. They would be more or less
linked depending on drug pressure and malaria trans-
mission level if QN pressure selects at least one of
them. In Kenya there is an association between two
DNNND repeats in the ms4760 Pfnhe microsatellite and
a reduced susceptibility to quinine in 29 P. falciparum
isolates [24]. This is consistent with the historic prece-
dent of the spread of drug resistance around the world.
T h ee m e r g e n c eo fc h l o r o q u i n er e s i s t a n c ei nA s i aw a s
followed by an initial introduction into East Africa and
spreading across the African continent. Geographic
proximity may explain plasmodial population migration.
Moreover, East African plasmodial populations may
exhibit genetic dissimilarities to other African popula-
tions [14].
As the QN response is controlled by multiple genes
with complex interactions, one can expect: i) higher sen-
sitivity to genetic background than if the response was
controlled by only one gene, ii) higher sensitivity to
parameters that may cause linkage disequilibrium
between genes and iii) various combinations of gene
polymorphisms may result in similar QNR phenotypes.
Conclusions
In summary, although studies have demonstrated that
Pfnhe-1 contributes to QNR [24], the present study and
another recent study [11] did not show an association
between Pfnhe-1 polymorphism and QNR. Currently,
Pfnhe-1 cannot be used as a QNR molecular marker
when evaluating field isolates, especially in Africa in the
context of a low level of quinine selection pressure.
Further studies, using more parasite samples from South
East Asia with reduced susceptibility to QN, are
required to confirm or reject the use of the Pfnhe-1
gene as a QNR marker in this geographic region.
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